DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b8c3v2/hyperlipidemia) has announced the addition of the "Hyperlipidemia - Pipeline Review, H2 2013" report to their offering.

'Hyperlipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperlipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperlipidemia.

Scope

- A snapshot of the global therapeutic scenario for Hyperlipidemia.

- A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Hyperlipidemia pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Amgen Inc.

Eli Lilly and Company

Tekmira Pharmaceuticals Corp.

Isis Pharmaceuticals, Inc.

Samyang Corporation

Daewoong Pharmaceutical Co., Ltd.

Dr. Reddy's Laboratories Limited

Santaris Pharma A/S

Idera Pharmaceuticals, Inc.

Yuhan Corporation

Regeneron Pharmaceuticals, Inc.

Immuron Limited

Hanall Pharmaceutical Co., Ltd.

Ahn-Gook Pharmaceutical Co., Ltd.

Catabasis Pharmaceuticals, Inc.

aRigen Pharmaceuticals, Inc.

Esperion Therapeutics, Inc.

FORMAC Pharmaceuticals N.V.

For more information visit http://www.researchandmarkets.com/research/b8c3v2/hyperlipidemia

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.